Management of recurrent nasopharyngeal carcinoma: current perspectives

Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 people. Being an extremely chemo- and radiosensitive disease, upfront treatment often consists in the association of intensity-mo...

Full description

Saved in:
Bibliographic Details
Published inOncoTargets and therapy Vol. 12; pp. 1583 - 1591
Main Authors Perri, F, Della Vittoria Scarpati, G, Caponigro, F, Ionna, F, Longo, F, Buonopane, S, Muto, P, Di Marzo, M, Pisconti, S, Solla, R
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2019
Taylor & Francis Ltd
Dove Medical Press
Subjects
Antimitotic agents
Antineoplastic agents
Cancer
Cancer therapies
Carcinoma
Care and treatment
Chemotherapy
Clinical trials
Dendritic cells
Development and progression
Health aspects
Immunotherapy
Infections
Medical prognosis
Melanoma
Metastasis
Oncology
Peptides
Radiation
Radiation therapy
Radiotherapy
Response rates
Review
Surgery
Throat cancer
Tumors
China
United States > US
Italy
Europe
nasopharyngeal carcinoma
re-irradiation
radioresistant
immunotherapy
poly-chemotherapy
Online AccessGet full text

Cover

More Information
Summary:Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 people. Being an extremely chemo- and radiosensitive disease, upfront treatment often consists in the association of intensity-modulated radiation therapy and concurrent cisplatin. Unfortunately, about 20% of the patients suffer from a radioresistant disease which recurs after upfront therapy. For these patients, mainly available therapeutic options consist in systemic therapy, in particular poly-chemotherapy. In those showing a single locoregional recurrence, chemotherapy is not considered to be the preferred approach and other different strategies may be employed. Re-irradiation and surgery are strategies that are always used more often, albeit related to high risk of morbidity. Immunotherapy and targeted therapy, such as heavy ions-based re-irradiations, are experimental but very intriguing options.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S188148